Labcorp Strengthens Clinical Services with New Acquisition
Enhancing its role in the diagnostics field
Labcorp, a major player in comprehensive laboratory services, has finalized the acquisition of specific assets from BioReference Health, a segment of OPKO Health. This move is designed to enhance Labcorp's abilities by broadening access to its clinical services, which are essential for both patients and healthcare providers.
Acquisition Details
This transaction includes BioReference Health's laboratory testing operations, particularly aimed at clinical diagnostics and women’s health. The focus extends to areas outside of New York and New Jersey. Along with this, Labcorp acquired crucial patient service centers, customer contracts, and various operational assets that together generate around $100 million each year. To obtain these assets, Labcorp has invested roughly $237.5 million.
Reasons for the Acquisition
Mark Schroeder, Labcorp's Executive Vice President, expressed his excitement about the acquisition, emphasizing that it reflects Labcorp's commitment to improving patient access to quality laboratory services. The goal of integrating these new assets is to enhance health outcomes for patients through the use of Labcorp’s extensive resources and expertise.
Insights from OPKO Health
Phillip Frost, M.D., the Chairman and CEO of OPKO, pointed out that choosing to sell these diagnostic assets is a crucial step for streamlining operations and steering BioReference Health towards profitability. This strategic shift allows OPKO to focus more on its primary clinical diagnostics in certain regions and on more lucrative testing segments, which generate about $400 million in annual revenue.
Significance of the Acquisition
Completing this acquisition not only supports Labcorp’s mission to provide improved services but also represents a shift in OPKO's direction towards more profitable opportunities. This partnership emphasizes both companies’ commitment to advancing healthcare through innovative diagnostics and testing solutions.
Advisory Roles in the Acquisition
In this noteworthy acquisition, Labcorp turned to Lazard for financial advice while relying on Hogan Lovells, Kilpatrick Townsend, and Parker Poe for legal representation. On the flip side, OPKO’s financial advisement was managed by Piper Sandler & Co., with legal counsel from Greenberg Traurig.
About Labcorp
Labcorp (NYSE: LH) leads the way in innovative laboratory services, assisting healthcare professionals and researchers to make informed choices. With a team of over 67,000 employees, Labcorp operates in around 100 countries, providing vital insights for developing new drugs and therapies that are key to enhancing health outcomes globally.
About OPKO Health
OPKO Health, Inc. (Nasdaq: OPK) is a flexible biopharmaceutical and diagnostics company aimed at creating a strong presence in rapidly growing markets through its discovery and technology capabilities. The company is dedicated to innovating and refining its operations to improve service delivery within the healthcare sector.
Frequently Asked Questions
What was the main goal of Labcorp's acquisition?
The primary goal was to improve access to quality laboratory services and broaden their clinical diagnostics reach.
How much did Labcorp invest in the acquisition?
Labcorp invested about $237.5 million to acquire the assets from BioReference Health.
Which specific areas does the acquisition focus on?
The acquisition centers on clinical diagnostics and women's health services beyond the New York and New Jersey regions.
What are OPKO's future plans following the transaction?
OPKO plans to focus on its core diagnostics and more profitable testing segments, which currently generate significant revenue.
How many countries does Labcorp operate in?
Labcorp provides its services in roughly 100 countries worldwide.
